John G. Gribben

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase 3 iLLUMINATE trial

2022 | Lékařská fakulta v Hradci Králové, 3. lékařská fakulta

Publikace